Chen P, Yu G, Zhang X, et al. - In a cohort study performed at Peking University First Hospital, researchers examined 1,210 patients with biopsy-proven IgA nephropathy, to determine the links of galactose-deficient IgA1 and galactose-deficient IgA1/C3 ratio with CKD progression event, defined as ESKD or 50% reduction in eGFR. At the time of biopsy, galactose-deficient IgA1 and complement component C3 levels in plasma were recorded. Participants were observed over a median duration of 43 months (interquartile range, 24–76 months). At the end of this time frame, 172 (14%) participants reached the CKD progression event. Findings revealed a link of plasma galactose-deficient IgA1/C3 ratio with CKD progression event in IgA nephropathy; this link was independent of clinical and biopsy features.